Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
The Majority of Current Non-Prescribers Anticipate Prescribing Xofigo within the Next Year, According to Findings from Decision Resources Group
BURLINGTON, Mass., Feb. 5, 2014 /PRNewswire/ -- Decision Resources Group finds that at six month post-launch in the United States, approximately two-thirds of surveyed U.S. medical oncologists have prescribed Algeta/Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to prescribe Xofigo to their metastatic castrate-resistant prostate cancer (mCRPC) patients within the next year. Notably, a significantly higher percentage of medical oncologists surveyed at six months post-launch express a high willingness to prescribe Xofigo compared with at one month post-launch.
Other key findings from the second wave of the LaunchTrends® Xofigo report:
Comments from Decision Resources Group Senior Director Rachel Webster, D.Phil., M.Sc.:
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.